#USA #New York #Securities Class Action #Regeneron Pharmaceuticals #Joseph Levi

Important Update for Investors

Attention all investors in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)! If you have purchased shares from August 1, 2025 to May 15, 2026, it’s time to take action as a class action lawsuit has been filed against the company. SueWallSt has issued an alert reminding shareholders of the impending deadline for filing to recover potential losses. Applications to serve as lead plaintiff must be submitted by September 14, 2026.

Background of the Lawsuit

The class action stems from claims that Regeneron provided materially misleading information regarding its Phase III Fianlimab-Libtayo Study. The lawsuit alleges that the company downplayed the risks related to a slowdown in event accrual during the clinical trials. Investors were led to believe that this slowdown was a positive indicator of treatment effectiveness rather than a signal of potential failure, causing undue optimism and inflated expectations about the study's results.

Allegations Against Regeneron

According to the filed complaint, the misleading statements resulted in a substantial decline in Regeneron’s stock price, particularly after a significant disclosure regarding the trial’s outcomes. It’s reported that shares fell approximately 13.95%, equating to a loss of over $102.09 per share from the period's peak to the final announcement of negative results. Investors who wish to seek compensation can reach out to Joseph E. Levi, Esq. at [email protected] or call 888-SueWallSt for more information on how to join the class action.

Details of the Claims

The complaint presents several key allegations:
1. Misrepresentation of Risk: Regeneron allegedly misrepresented how the prolonged slowdown in event accrual was perceived positively, while the reality posed significant risks to the trial’s designed outcomes.
2. Flawed Statistical Assumptions: Investors were not informed that the preliminary statistical assumptions guiding the trial might have been materially flawed, increasing the risk of not achieving the trial's primary endpoint.
3. Promoted Expectations: The lawsuit contends that the optimistic framing of event accrual misled investors into developing unrealistic expectations regarding the trial’s success, misrepresenting the risks associated with its statistical performance.

The Stakes for Investors

This case highlights crucial questions regarding disclosure obligations in the biotechnology sector. The attorneys representing the investors are stressing the need for transparency, especially when investors are making critical financial decisions based on potentially misleading information. Lack of clarity could have severe repercussions on shareholder interests, particularly when the stakes involve public health and investment risk in clinical trials.

Next Steps for Affected Investors

If you purchased Regeneron’s shares during the specified class period and suffered losses, it is important to act now to potentially partake in the recovery. Here’s what you need to do:

• - Contact a Securities Attorney: Reach out to legal professionals like Joseph Levi, who can provide a consultation on your eligibility and the process involved in joining the class action lawsuit.
• - Review Your Trading Records: Gather documentation of your purchases and sales of REGN shares during the defined timeline to establish your claim.
• - Apply by the Deadline: Ensure that your application to act as a lead plaintiff, if applicable, is submitted before the deadline on September 14, 2026.

Conclusion

There is still time for affected investors to take meaningful action regarding their investment in Regeneron Pharmaceuticals. The upcoming litigation will scrutinize the transparency of disclosures made by the company and could determine the future financial recoveries of investors who feel misled. Don’t hesitate to seek further information on your rights as a shareholder and ensure that you protect your financial interests during this critical period.